131 related articles for article (PubMed ID: 16762314)
1. IK682, a tight binding inhibitor of TACE.
Niu X; Umland S; Ingram R; Beyer BM; Liu YH; Sun J; Lundell D; Orth P
Arch Biochem Biophys; 2006 Jul; 451(1):43-50. PubMed ID: 16762314
[TBL] [Abstract][Full Text] [Related]
2. A molecular modeling analysis of novel non-hydroxamate inhibitors of TACE.
Sheppeck JE; Tebben A; Gilmore JL; Yang A; Wasserman ZR; Decicco CP; Duan JJ
Bioorg Med Chem Lett; 2007 Mar; 17(5):1408-12. PubMed ID: 17188861
[TBL] [Abstract][Full Text] [Related]
3. Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.
Duan JJ; Chen L; Wasserman ZR; Lu Z; Liu RQ; Covington MB; Qian M; Hardman KD; Magolda RL; Newton RC; Christ DD; Wexler RR; Decicco CP
J Med Chem; 2002 Nov; 45(23):4954-7. PubMed ID: 12408705
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II: optimization of the S3' pocket.
Mazzola RD; Zhu Z; Sinning L; McKittrick B; Lavey B; Spitler J; Kozlowski J; Neng-Yang S; Zhou G; Guo Z; Orth P; Madison V; Sun J; Lundell D; Niu X
Bioorg Med Chem Lett; 2008 Nov; 18(21):5809-14. PubMed ID: 18835710
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket.
Huang A; Joseph-McCarthy D; Lovering F; Sun L; Wang W; Xu W; Zhu Y; Cui J; Zhang Y; Levin JI
Bioorg Med Chem; 2007 Sep; 15(18):6170-81. PubMed ID: 17606376
[TBL] [Abstract][Full Text] [Related]
6. Identification of potent and selective TACE inhibitors via the S1 pocket.
Condon JS; Joseph-McCarthy D; Levin JI; Lombart HG; Lovering FE; Sun L; Wang W; Xu W; Zhang Y
Bioorg Med Chem Lett; 2007 Jan; 17(1):34-9. PubMed ID: 17064892
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, preliminary biological evaluation and molecular modeling of some new heterocyclic inhibitors of TACE.
Sengupta P; Puri CS; Chokshi HA; Sheth CK; Midha AS; Chitturi TR; Thennati R; Murumkar PR; Yadav MR
Eur J Med Chem; 2011 Nov; 46(11):5549-55. PubMed ID: 21963348
[TBL] [Abstract][Full Text] [Related]
8. Discovery of beta-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors.
Duan JJ; Chen L; Lu Z; Xue CB; Liu RQ; Covington MB; Qian M; Wasserman ZR; Vaddi K; Christ DD; Trzaskos JM; Newton RC; Decicco CP
Bioorg Med Chem Lett; 2008 Jan; 18(1):241-6. PubMed ID: 18032037
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors: Part I--discovery of two binding modes.
Zhu Z; Mazzola R; Sinning L; McKittrick B; Niu X; Lundell D; Sun J; Orth P; Guo Z; Madison V; Ingram R; Beyer BM
J Med Chem; 2008 Feb; 51(4):725-36. PubMed ID: 18247549
[TBL] [Abstract][Full Text] [Related]
10. The discovery of novel tartrate-based TNF-alpha converting enzyme (TACE) inhibitors.
Rosner KE; Guo Z; Orth P; Shipps GW; Belanger DB; Chan TY; Curran PJ; Dai C; Deng Y; Girijavallabhan VM; Hong L; Lavey BJ; Lee JF; Li D; Liu Z; Popovici-Muller J; Ting PC; Vaccaro H; Wang L; Wang T; Yu W; Zhou G; Niu X; Sun J; Kozlowski JA; Lundell DJ; Madison V; McKittrick B; Piwinski JJ; Shih NY; Arshad Siddiqui M; Strickland CO
Bioorg Med Chem Lett; 2010 Feb; 20(3):1189-93. PubMed ID: 20022498
[TBL] [Abstract][Full Text] [Related]
11. Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Duan JJ; Chen L; Lu Z; Jiang B; Asakawa N; Sheppeck JE; Liu RQ; Covington MB; Pitts W; Kim SH; Decicco CP
Bioorg Med Chem Lett; 2007 Jan; 17(1):266-71. PubMed ID: 17027261
[TBL] [Abstract][Full Text] [Related]
12. Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.
Duan JJ; Lu Z; Wasserman ZR; Liu RQ; Covington MB; Decicco CP
Bioorg Med Chem Lett; 2005 Jun; 15(12):2970-3. PubMed ID: 15908214
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the binding sites of matrix metalloproteinases and tumor necrosis factor-alpha converting enzyme: implications for selectivity.
Lukacova V; Zhang Y; Kroll DM; Raha S; Comez D; Balaz S
J Med Chem; 2005 Apr; 48(7):2361-70. PubMed ID: 15801829
[TBL] [Abstract][Full Text] [Related]
14. Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.
Xue CB; He X; Corbett RL; Roderick J; Wasserman ZR; Liu RQ; Jaffee BD; Covington MB; Qian M; Trzaskos JM; Newton RC; Magolda RL; Wexler RR; Decicco CP
J Med Chem; 2001 Oct; 44(21):3351-4. PubMed ID: 11585440
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel spirocyclopropyl hydroxamate and carboxylate compounds as TACE inhibitors.
Guo Z; Orth P; Wong SC; Lavey BJ; Shih NY; Niu X; Lundell DJ; Madison V; Kozlowski JA
Bioorg Med Chem Lett; 2009 Jan; 19(1):54-7. PubMed ID: 19054672
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and activity of quinolinylmethyl P1' alpha-sulfone piperidine hydroxamate inhibitors of TACE.
Zhang C; Lovering F; Behnke M; Zask A; Sandanayaka V; Sun L; Zhu Y; Xu W; Zhang Y; Levin JI
Bioorg Med Chem Lett; 2009 Jul; 19(13):3445-8. PubMed ID: 19464885
[TBL] [Abstract][Full Text] [Related]
17. Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Sheppeck JE; Gilmore JL; Tebben A; Xue CB; Liu RQ; Decicco CP; Duan JJ
Bioorg Med Chem Lett; 2007 May; 17(10):2769-74. PubMed ID: 17368021
[TBL] [Abstract][Full Text] [Related]
18. Crystal structure of the catalytic domain of human tumor necrosis factor-alpha-converting enzyme.
Maskos K; Fernandez-Catalan C; Huber R; Bourenkov GP; Bartunik H; Ellestad GA; Reddy P; Wolfson MF; Rauch CT; Castner BJ; Davis R; Clarke HR; Petersen M; Fitzner JN; Cerretti DP; March CJ; Paxton RJ; Black RA; Bode W
Proc Natl Acad Sci U S A; 1998 Mar; 95(7):3408-12. PubMed ID: 9520379
[TBL] [Abstract][Full Text] [Related]
19. Novel thiol-based TACE inhibitors. Part 2: Rational design, synthesis, and SAR of thiol-containing aryl sulfones.
Bandarage UK; Wang T; Come JH; Perola E; Wei Y; Rao BG
Bioorg Med Chem Lett; 2008 Jan; 18(1):44-8. PubMed ID: 18054488
[TBL] [Abstract][Full Text] [Related]
20. Structure-based rational design of peptide hydroxamic acid inhibitors to target tumor necrosis factor-α converting enzyme as potential therapeutics for hepatitis.
Wu D; Gu Q; Zhao N; Xia F; Li Z
J Drug Target; 2015 Dec; 23(10):936-42. PubMed ID: 26061299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
